(from l-r) Avner Geva, Vensica Therapeutics CEO & Co Founder; Avi Eftel, Vensica Therapeutics CTO & Co Founder
Vensica Medical is an Israeli medtech startup that offers a type of needle-free tech to inject meds into a person’s bladder for the treatment of overactive bladder (OAB). The firm raised $11 million in funding led by Israel Biotech Fund (IBF).
The investment will fund the company’s upcoming Phase 2 clinical trials across the United States and Europe for its treatment of overactive bladder using botulinum toxin A (Xeomin®) delivered through a proprietary, needle-free device. The company has now raised $30 million to date.
Overactive bladder is a common condition that causes a sudden, urgent need to urinate that’s difficult to control. You may also experience frequent urination, both during the day and night (nocturia), and leakage of urine (urgency incontinence).
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
The Mayo Clinic explains that overactive bladder happens when the muscles of the bladder start to tighten on their own even when the amount of urine in the bladder is low. These are called involuntary contractions. They cause an urgent need to urinate.
Aging increases the risk of overactive bladder. So does being female. Conditions such as enlarged prostate and diabetes also can increase the risk.
Xeomin® works by blocking nerve signals to the muscles, causing them to relax. This can help to improve the appearance of wrinkles and lines on the face, as well as treat certain medical conditions.
Founded in 2015 by Avner Geva, (Yale, B.Sc, Technion, M.Sc), Vensica is a urology therapeutics company developing a unique platform for drug delivery for several urinary bladder indications, based on a proprietary ultrasound-assisted drug delivery system.
“We are thrilled to have the support of leading investors and partners who share our vision of transforming overactive bladder treatment,” remarked Avner Geva, CEO of Vensica. “This funding will allow us to push forward with Phase 2 trials and move one step closer to bringing this innovative therapy to the patients who need it.”
As part of its strategic partnership with Merz, Vensica has secured exclusive rights to Xeomin® in needle-less therapeutic application in several urologic indications and will benefit from Merz’s clinical development support. This collaboration marks a significant step forward in the company’s goal of delivering next-generation urology treatments.
